The effects of statins on the mevalonic acid pathway in recombinant yeast strains expressing human HMG-CoA reductase

BMC Biotechnology

Volumn 13, Issue , 2013, Pages

  Maciejak, Agata ^a   Leszczynska, Agata ^a   Warchol, Ilona ^a   Gora, Monika ^a   Kaminska, Joanna ^a   Plochocka, Danuta ^a   Wysocka Kapcinska, Monika ^a   Tulacz, Dorota ^a   Siedlecka, Joanna ^a   Swiezewska, Ewa ^a   Sojka, Maciej ^b   Danikiewicz, Witold ^b   Odolczyk, Norbert ^a   Szkopinska, Anna ^a   Sygitowicz, Grazyna ^c   Burzynska, Beata ^a  

^a INSTITUTE OF BIOCHEMISTRY AND BIOPHYSICS   (Poland)

^b INSTITUTE OF ORGANIC CHEMISTRY   (Poland)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Heterologous proteins; HMG CoA reductase; Mevalonate pathway; Statins; Yeast expression system

Indexed keywords

HETEROLOGOUS PROTEINS; HMG-COA REDUCTASE; MEVALONATE PATHWAY; STATINS; YEAST EXPRESSION;

BIOCHEMISTRY; BIOSYNTHESIS; ENZYMES; GENE EXPRESSION; LAKES; LIPIDS; PROTEINS; YEAST;

ALCOHOLS;

ACETYL COENZYME A ACETYLTRANSFERASE; ATORVASTATIN; DOLICHOL; ERGOSTEROL; FARNESYL TRANS TRANSFERASE; FLUINDOSTATIN; HIGH MOBILITY GROUP B1 PROTEIN; HIGH MOBILITY GROUP B2 PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LANOSTEROL; MESSENGER RNA; MEVALONIC ACID; ROSUVASTATIN; SIMVASTATIN; SQUALENE; SQUALENE MONOOXYGENASE; ZYMOSTEROL;

ARTICLE; CELL METABOLISM; DRUG EFFECT; FUNGUS GROWTH; GENE EXPRESSION SYSTEM; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PRENYLATION; SACCHAROMYCES CEREVISIAE; STEROL SYNTHESIS; YEAST CELL;

SACCHAROMYCES CEREVISIAE;

FATTY ACIDS, MONOUNSATURATED; FLUOROBENZENES; FUNGAL PROTEINS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; ISOENZYMES; MEVALONIC ACID; ORGANISMS, GENETICALLY MODIFIED; PYRIMIDINES; PYRROLES; SACCHAROMYCES CEREVISIAE; SIMVASTATIN; STEROLS; SULFONAMIDES; TERPENES;

EID: 84883197572     PISSN: None     EISSN: 14726750     Source Type: Journal    
DOI: 10.1186/1472-6750-13-68     Document Type: Article

References (34)

1. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995, 333:1301-1308. 10.1056/NEJM199511163332001, 7566020.
2. Prosser LA, Stinnett AA, Goldman PA, Williams LW, Hunink MG, Goldman L, Weinstein MC. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Ann Intern Med 2000, 132:769-779.
3. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, ASCOT investigators Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361:1149-1158. 10.1016/S0140-6736(03)12948-0, 12686036, ASCOT investigators.
4. Buhaescu I, Izzedine H. Mevalonate pathway: a review of clinic and therapeutical implications. Clin Biochem 2007, 40:575-584. 10.1016/j.clinbiochem.2007.03.016, 17467679.
5. Evans M, Rees A. Effects of HMG-CoA reductase inhibitors on skeletal muscle. Drug Saf 2002, 25:649-663. 10.2165/00002018-200225090-00004, 12137559.
6. Onofrei MD, Butler KL, Fuke DC, Miller HB. Safety of statin therapy in patients with preexisting liver disease. Pharmacotherapy 2008, 28:522-529. 10.1592/phco.28.4.522, 18363535.
7. Zhou Q, Liao JK. Statins and cardiovascular disease: from cholesterol lowering to pleiotropy. Curr Pharm Des 2009, 15:467-478. 10.2174/138161209787315684, 2896785, 19199975.
8. Botstein D, Chervitz SA, Cherry JM. Yeast as a model organism. Science 1997, 277:1259-1260. 10.1126/science.277.5330.1259, 3039837, 9297238.
9. Sturgeon CM, Kemmer D, Anderson HJ, Roberge M. Yeast as a tool to uncover the cellular targets of drugs. Biotechnol J 2006, 1:289-298. 10.1002/biot.200500039, 16897709.
10. Marjanovic J, Chalupska D, Patenode C, Coster A, Arnold E, Ye A, Anesi G, Lu Y, Okun I, Tkachenko S, Haselkorn R, Gornicki P. Recombinant yeast screen for new inhibitors of human acetyl-CoA carboxylase 2 identifies potential drugs to treat obesity. Proc Natl Acad Sci USA 2010, 107:9093-9098. 10.1073/pnas.1003721107, 2889071, 20439761.
11. Wysocka-Kapcinska M, Lutyk-Nadolska J, Kiliszek M, Plochocka D, Maciag M, Leszczynska A, Rytka J, Burzynska B. Functional expression of human HMG-CoA reductase in Saccharomyces cerevisiae: a system to analyse normal and mutated versions of the enzyme in the context of statin treatment. J Appl Microbiol 2009, 106:895-902. 10.1111/j.1365-2672.2008.04060.x, 19187128.
12. Nielsen J. Systems biology of lipid metabolism: from yeast to human. FEBS Lett 2009, 583:3905-3913. 10.1016/j.febslet.2009.10.054, 19854183.
13. Smith AM, Ammar R, Nislow C, Giaever G. A survey of yeast genomic assays for drug and target discovery. Pharmacol Ther 2010, 127:156-164. 10.1016/j.pharmthera.2010.04.012, 2923554, 20546776.
14. Morikawa S, Murakami T, Yamazaki H, Izumi A, Saito Y, Hamakubo T, Kodama T. Analysis of the global RNA expression profiles of skeletal muscle cells treated with statins. J Atheroscler Thromb 2005, 12:121-131. 10.5551/jat.12.121, 16020911.
15. Leszczynska A, Gora M, Plochocka D, Hoser G, Szkopinska A, Koblowska M, Iwanicka-Nowicka R, Kotlinski M, Rawa K, Kiliszek M, Burzynska B. Different statins produce highly divergent changes in gene expression profiles of human hepatoma cells: a pilot study. Acta Biochim Pol 2011, 58:635-639.
16. Gerber R, Ryan JD, Clark DS. Cell-based screen of HMG-CoA reductase inhibitors and expression regulators using LC-MS. Anal Biochem 2004, 329:28-34. 10.1016/j.ab.2004.03.023, 15136164.
17. Hagemenas FC, Illingworth DR. Cholesterol homeostasis in mononuclear leukocytes from patients with familial hypercholesterolemia treated with lovastatin. Arteriosclerosis 1989, 9:355-361. 10.1161/01.ATV.9.3.355, 2719596.
18. Leszczynska A, Burzynska B, Plochocka D, Kaminska J, Zimnicka M, Kania M, Kiliszek M, Wysocka-Kapcinska M, Danikiewicz W, Szkopinska A. Investigating the effects of statins on cellular lipid metabolism using a yeast expression system. PLoS One 2009, 4:e8499. 10.1371/journal.pone.0008499, 2796174, 20041128.
19. Mabuchi H, Higashikata T, Kawashiri M, Katsuda S, Mizuno M, Nohara A, Inazu A, Koizumi J, Kobayashi J. Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients. J Atheroscler Thromb 2005, 2:111-119.
20. Rundek T, Naini A, Sacco R. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. Arch Neurol 2004, 61:889-892. 10.1001/archneur.61.6.889, 15210526.
21. Swiezewska E, Danikiewicz W. Polyisoprenoids: structure, biosynthesis and function. Prog Lipid Res 2005, 44:235-258. 10.1016/j.plipres.2005.05.002, 16019076.
22. Bergamini E. Dolichol: an essential part in the antioxidant machinery of cell membranes?. Biogerontology 2003, 4:337-339.
23. Larsson O, Wejde J. Dolichol delays G1-arrest for one cell cycle in human fibroblasts subjected to depletion of serum or mevalonate. J Cell Sci 1992, 103:1065-1072.
24. Baksi K, Tavarez-Pagan JJ, Martinez JA, Banerjee DK. Unique structural motif supports mannosylphospho dolichol synthase: an important angiogenesis regulator. Cirr Drug Targets 2008, 9:262-271.
25. Endres M, Laufs U. Effects of statins on endothelium and signaling mechanisms. Stroke 2004, 35:2708-2711. 10.1161/01.STR.0000143319.73503.38, 15375300.
26. Takemoto M, Node K, Nakagami H, Liao Y, Grimm M, Takemoto Y, Kitakaze M, Liao JK. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest 2001, 108:1429-1437. 209420, 11714734.
27. Fowler DM, Cooper SJ, Stephany JJ, Hendon N, Nelson S, Fields S. Suppression of statin effectiveness by copper and zinc in yeast and human cells. Mol Biosyst 2011, 7:533-544. 10.1039/c0mb00166j, 3138400, 21085730.
28. Takami T, Fang Y, Zhou X, Jaiseng W, Ma Y, Kuno T. A genetic and pharmacological analysis of isoprenoid pathway by LC-MS/MS in fission yeast. PLoS One 2012, 7:e49004. 10.1371/journal.pone.0049004, 3492200, 23145048.
29. Janke C, Magiera MM, Rathfelder N, Taxis C, Reber S, Maekawa H, Moreno-Borchart A, Doenges G, Schwob E, Schiebel E, Knop M. A versatile toolbox for PCR-based tagging of yeast genes: new fluorescent proteins, more markers and promoter substitution cassettes. Yeast 2004, 11:947-962.
30. Sato M, Fujisaki S, Sato K, Nishimura Y, Nakano A. Yeast Saccharomyces cerevisiae has two cis-prenyltransferases with different properties and localizations. Implication for their distinct physiological roles in dolichol synthesis. Genes Cells 2001, 6:495-506. 10.1046/j.1365-2443.2001.00438.x, 11442630.
31. Rose M, Winston F, Hieter P. Methods in Yeast Genetics. A Cold Spring Harbor Laboratory Course 1990, New York: Cold Spring Harbor Press.
32. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001, 29:e45. 10.1093/nar/29.9.e45, 55695, 11328886.
33. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST©) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 2002, 9:e36.
34. Volland C, Urban-Grimal D, Géraud G, Haguenauer-Tsapis R. Endocytosis and degradation of the yeast uracil permease under adverse conditions. J Biol Chem 1994, 269:9833-9841.